Nordic Nanovector ASA – Streaming details for EGM

Report this content

Oslo, Norway, 19 October 2020

Nordic Nanovector ASA (the "Company") will carry out an Extraordinary General Meeting (EGM) on 21 October 2020 at 10:00 CET. The EGM will be held at the Company's offices in Kjelsåsveien 168, 0884 Oslo, Norway. Following the Covid-19 pandemic, shareholders have been encouraged to exercise their shareholder rights without attending in person through advance voting or by providing a proxy to the Chairman of the board of directors or the person he authorises within 19 October 2020 16:00 CET. The EGM will be live streamed. The EGM will be held in English and can be followed at:

For further information, please contact:

IR enquiries

Malene Brondberg, CFO

Cell: +44 7561 431 762


Media Enquiries

Mark Swallow/Frazer Hall/David Dible (Citigate Dewe Rogerson)

Tel: +44 203 926 8535


About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector retains global marketing rights to Betalutin® and intends to actively participate in the commercialisation of Betalutin® in the US and other major markets.

Further information can be found at